Skip to main content

Market Overview

Why OncoCyte's Stock Is Trading Higher Today


OncoCyte (NYSE: OCX) shares are trading higher on Tuesday after the company and Burning Rock announced an exclusive in-licensing agreement for the DetermaRx treatment stratification test.

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers.

OncoCyte shares were trading up 20.05% at $2.54. The stock has a 52-week high of $3.51 and a 52-week low of $1.15.


Related Articles (OCX)

View Comments and Join the Discussion!

Posted-In: why it's movingNews Penny Stocks

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at